Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, […]

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was acquired at an average cost of $10.19 per share, for a total transaction of $10,190.00. Following the purchase, the director owned 17,592 shares in the company, […]

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares in the company, […]

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares in the […]